Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antipsychotic Agents | 39 | 2021 | 3057 | 4.630 |
Why?
|
Receptors, Dopamine | 14 | 2013 | 295 | 2.840 |
Why?
|
Receptors, Dopamine D2 | 30 | 2021 | 475 | 2.790 |
Why?
|
Prosencephalon | 16 | 2017 | 303 | 2.330 |
Why?
|
Receptor, Serotonin, 5-HT2A | 7 | 2018 | 63 | 1.690 |
Why?
|
Receptor, Serotonin, 5-HT1A | 6 | 2018 | 53 | 1.570 |
Why?
|
Risperidone | 9 | 2009 | 383 | 1.460 |
Why?
|
Receptors, Serotonin | 8 | 2016 | 201 | 1.440 |
Why?
|
Schizophrenia | 13 | 2021 | 6882 | 1.250 |
Why?
|
Receptors, Glutamate | 7 | 2008 | 232 | 1.170 |
Why?
|
Receptors, Dopamine D1 | 15 | 2017 | 291 | 1.150 |
Why?
|
Receptors, AMPA | 9 | 2017 | 332 | 1.140 |
Why?
|
Rats, Sprague-Dawley | 52 | 2018 | 8300 | 1.100 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 9 | 2017 | 896 | 1.090 |
Why?
|
Rats | 72 | 2021 | 24252 | 1.080 |
Why?
|
Piperazines | 7 | 2019 | 2488 | 1.050 |
Why?
|
Depressive Disorder, Major | 5 | 2022 | 4639 | 1.030 |
Why?
|
Receptors, Dopamine D4 | 20 | 2012 | 171 | 1.020 |
Why?
|
Pirenzepine | 5 | 2003 | 115 | 1.010 |
Why?
|
Excitatory Amino Acid Antagonists | 6 | 2016 | 449 | 1.000 |
Why?
|
Oxazepines | 3 | 2012 | 18 | 0.990 |
Why?
|
Autoradiography | 28 | 2009 | 745 | 0.990 |
Why?
|
Brain Chemistry | 10 | 2009 | 982 | 0.980 |
Why?
|
Isoxazoles | 2 | 2018 | 216 | 0.960 |
Why?
|
Piperidines | 4 | 2018 | 1602 | 0.960 |
Why?
|
Resilience, Psychological | 2 | 2021 | 677 | 0.910 |
Why?
|
Isoindoles | 2 | 2013 | 41 | 0.890 |
Why?
|
Dopamine Agonists | 6 | 2019 | 355 | 0.880 |
Why?
|
Antidepressive Agents | 5 | 2021 | 2838 | 0.860 |
Why?
|
Dopamine | 14 | 2017 | 1591 | 0.860 |
Why?
|
Putamen | 11 | 2007 | 291 | 0.830 |
Why?
|
Nucleus Accumbens | 14 | 2006 | 366 | 0.770 |
Why?
|
Psychotropic Drugs | 2 | 2018 | 894 | 0.760 |
Why?
|
Caudate Nucleus | 10 | 2007 | 393 | 0.760 |
Why?
|
Membrane Transport Proteins | 10 | 2003 | 1031 | 0.750 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 3 | 2016 | 43 | 0.740 |
Why?
|
Receptors, Oxytocin | 1 | 2020 | 66 | 0.720 |
Why?
|
Stress Disorders, Traumatic | 1 | 2020 | 53 | 0.710 |
Why?
|
Limbic System | 6 | 1999 | 426 | 0.700 |
Why?
|
Receptors, Dopamine D3 | 8 | 2021 | 110 | 0.690 |
Why?
|
Dibenzothiazepines | 5 | 2003 | 103 | 0.680 |
Why?
|
Dopamine Antagonists | 16 | 2013 | 296 | 0.680 |
Why?
|
Serotonin | 7 | 2021 | 1017 | 0.670 |
Why?
|
Chromosome Disorders | 1 | 2022 | 514 | 0.670 |
Why?
|
Dibenzocycloheptenes | 7 | 2012 | 27 | 0.650 |
Why?
|
Receptors, Adrenergic, alpha | 1 | 2018 | 149 | 0.650 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 7 | 2016 | 322 | 0.630 |
Why?
|
Brain | 22 | 2017 | 26388 | 0.620 |
Why?
|
Paroxetine | 3 | 2016 | 182 | 0.610 |
Why?
|
Object Attachment | 1 | 2020 | 313 | 0.590 |
Why?
|
Animals | 93 | 2022 | 168768 | 0.590 |
Why?
|
Glucosides | 1 | 2021 | 451 | 0.580 |
Why?
|
Anti-Anxiety Agents | 1 | 2019 | 390 | 0.580 |
Why?
|
Oxidopamine | 12 | 2005 | 169 | 0.580 |
Why?
|
Corpus Striatum | 10 | 2009 | 1221 | 0.560 |
Why?
|
Norepinephrine | 3 | 2021 | 909 | 0.550 |
Why?
|
Oxytocin | 1 | 2020 | 394 | 0.550 |
Why?
|
Psychotherapy | 3 | 2022 | 1642 | 0.550 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2020 | 703 | 0.540 |
Why?
|
Tritium | 12 | 2013 | 745 | 0.540 |
Why?
|
Radioligand Assay | 14 | 2012 | 374 | 0.540 |
Why?
|
Cerebral Cortex | 8 | 2018 | 5709 | 0.530 |
Why?
|
Thiazoles | 2 | 2013 | 1483 | 0.530 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 9 | 2015 | 3658 | 0.520 |
Why?
|
Urea | 1 | 2017 | 450 | 0.520 |
Why?
|
Synaptic Transmission | 7 | 2014 | 1178 | 0.520 |
Why?
|
Bipolar Disorder | 4 | 2021 | 5027 | 0.500 |
Why?
|
Neurology | 1 | 2023 | 763 | 0.500 |
Why?
|
Haloperidol | 8 | 2007 | 397 | 0.500 |
Why?
|
Asperger Syndrome | 1 | 2015 | 63 | 0.500 |
Why?
|
Neostriatum | 8 | 2008 | 250 | 0.500 |
Why?
|
Cholecalciferol | 1 | 2019 | 535 | 0.500 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 845 | 0.490 |
Why?
|
Imipramine | 1 | 2014 | 97 | 0.480 |
Why?
|
Drug Discovery | 3 | 2018 | 1058 | 0.460 |
Why?
|
Hyperkinesis | 5 | 2005 | 89 | 0.460 |
Why?
|
Restless Legs Syndrome | 1 | 2016 | 228 | 0.460 |
Why?
|
Pyridines | 4 | 2012 | 2825 | 0.430 |
Why?
|
Citalopram | 1 | 2016 | 403 | 0.430 |
Why?
|
Receptors, Kainic Acid | 5 | 2008 | 88 | 0.430 |
Why?
|
Nerve Tissue Proteins | 10 | 2003 | 4463 | 0.420 |
Why?
|
Adrenergic Agents | 5 | 2009 | 70 | 0.410 |
Why?
|
Receptors, Adrenergic, alpha-2 | 1 | 2012 | 64 | 0.410 |
Why?
|
Parkinson Disease | 2 | 2017 | 2775 | 0.410 |
Why?
|
Azabicyclo Compounds | 1 | 2012 | 68 | 0.410 |
Why?
|
Alzheimer Disease | 3 | 2023 | 8038 | 0.400 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2021 | 10943 | 0.400 |
Why?
|
Schizophrenic Psychology | 2 | 2017 | 1678 | 0.400 |
Why?
|
Naphthalenes | 1 | 2012 | 194 | 0.390 |
Why?
|
Vitamins | 1 | 2019 | 1623 | 0.390 |
Why?
|
Membrane Glycoproteins | 10 | 2003 | 3771 | 0.380 |
Why?
|
Clozapine | 8 | 2007 | 498 | 0.380 |
Why?
|
Dopamine Uptake Inhibitors | 2 | 2012 | 312 | 0.370 |
Why?
|
Benzodiazepines | 9 | 2016 | 1101 | 0.360 |
Why?
|
Fluoxetine | 1 | 2014 | 749 | 0.360 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1343 | 0.350 |
Why?
|
Metabolomics | 1 | 2018 | 1485 | 0.350 |
Why?
|
Receptors, Adrenergic | 1 | 2009 | 155 | 0.350 |
Why?
|
Hippocampus | 10 | 2018 | 3675 | 0.350 |
Why?
|
Phencyclidine | 1 | 2009 | 61 | 0.350 |
Why?
|
Receptors, Muscarinic | 1 | 2009 | 156 | 0.340 |
Why?
|
Drug Evaluation, Preclinical | 5 | 2018 | 1375 | 0.340 |
Why?
|
Extrapyramidal Tracts | 3 | 2002 | 18 | 0.330 |
Why?
|
Aporphines | 4 | 2008 | 32 | 0.320 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 2873 | 0.320 |
Why?
|
Behavior, Animal | 3 | 2013 | 1881 | 0.310 |
Why?
|
Anxiety Disorders | 1 | 2019 | 2690 | 0.310 |
Why?
|
Carrier Proteins | 9 | 2003 | 5023 | 0.290 |
Why?
|
Renal Dialysis | 1 | 2016 | 1783 | 0.290 |
Why?
|
Glutamic Acid | 3 | 2014 | 1169 | 0.280 |
Why?
|
Rats, Wistar | 5 | 2021 | 1892 | 0.270 |
Why?
|
Sexual Behavior | 1 | 2016 | 2055 | 0.270 |
Why?
|
Amphetamine | 6 | 2014 | 225 | 0.270 |
Why?
|
Parkinsonian Disorders | 3 | 2005 | 275 | 0.270 |
Why?
|
Animals, Newborn | 12 | 2009 | 2726 | 0.270 |
Why?
|
Vitamin D | 1 | 2019 | 3224 | 0.270 |
Why?
|
Binding, Competitive | 7 | 2009 | 1157 | 0.260 |
Why?
|
Tetrahydronaphthalenes | 3 | 2016 | 89 | 0.260 |
Why?
|
Adrenergic Uptake Inhibitors | 3 | 2006 | 189 | 0.260 |
Why?
|
Male | 65 | 2022 | 350115 | 0.250 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4266 | 0.250 |
Why?
|
Kainic Acid | 3 | 1999 | 199 | 0.240 |
Why?
|
Propylamines | 1 | 2005 | 165 | 0.240 |
Why?
|
Salicylamides | 5 | 1999 | 33 | 0.240 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 2535 | 0.230 |
Why?
|
Denervation | 3 | 2003 | 278 | 0.230 |
Why?
|
Presynaptic Terminals | 2 | 2003 | 302 | 0.230 |
Why?
|
Psychotic Disorders | 2 | 2017 | 3046 | 0.230 |
Why?
|
Apomorphine | 3 | 2009 | 150 | 0.230 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2007 | 503 | 0.230 |
Why?
|
Fluphenazine | 2 | 2006 | 36 | 0.230 |
Why?
|
Immunotherapy | 2 | 2023 | 4446 | 0.220 |
Why?
|
Alkylating Agents | 2 | 2000 | 139 | 0.220 |
Why?
|
Saudi Arabia | 1 | 2023 | 209 | 0.210 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 8 | 2017 | 422 | 0.210 |
Why?
|
Humans | 39 | 2023 | 744366 | 0.200 |
Why?
|
Afferent Pathways | 1 | 2003 | 302 | 0.200 |
Why?
|
Basal Ganglia Diseases | 1 | 2002 | 149 | 0.200 |
Why?
|
Neurobiology | 1 | 2022 | 121 | 0.200 |
Why?
|
Levodopa | 2 | 2016 | 219 | 0.190 |
Why?
|
Striatonigral Degeneration | 1 | 2000 | 13 | 0.190 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2022 | 351 | 0.190 |
Why?
|
Time | 2 | 2017 | 542 | 0.190 |
Why?
|
Drug Dosage Calculations | 1 | 2021 | 114 | 0.180 |
Why?
|
Up-Regulation | 4 | 2006 | 4222 | 0.180 |
Why?
|
Anxiety | 1 | 2015 | 4293 | 0.180 |
Why?
|
Visual Cortex | 2 | 1999 | 1149 | 0.180 |
Why?
|
Analgesics, Opioid | 1 | 2016 | 3677 | 0.180 |
Why?
|
Neurotransmitter Agents | 2 | 2015 | 647 | 0.180 |
Why?
|
Depression | 3 | 2015 | 7759 | 0.180 |
Why?
|
Biological Psychiatry | 1 | 1999 | 25 | 0.180 |
Why?
|
Neopterin | 1 | 2019 | 56 | 0.180 |
Why?
|
Nitric Oxide Synthase | 1 | 2002 | 915 | 0.170 |
Why?
|
Motor Activity | 8 | 2012 | 2715 | 0.170 |
Why?
|
Skiing | 1 | 1999 | 24 | 0.170 |
Why?
|
Kynurenine | 1 | 2019 | 139 | 0.170 |
Why?
|
Microdialysis | 2 | 2012 | 158 | 0.160 |
Why?
|
Neuronal Plasticity | 3 | 2003 | 1423 | 0.160 |
Why?
|
Protein Binding | 7 | 2013 | 9384 | 0.150 |
Why?
|
Zinc | 1 | 2022 | 684 | 0.150 |
Why?
|
Dietary Supplements | 2 | 2022 | 3296 | 0.150 |
Why?
|
Chromosome Deletion | 1 | 2022 | 1401 | 0.150 |
Why?
|
Quality of Life | 2 | 2016 | 12802 | 0.150 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2016 | 25 | 0.150 |
Why?
|
Quinolines | 3 | 2000 | 732 | 0.140 |
Why?
|
Music Therapy | 1 | 2018 | 102 | 0.140 |
Why?
|
Organ Specificity | 5 | 2012 | 2008 | 0.140 |
Why?
|
Massage | 1 | 2016 | 85 | 0.140 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2018 | 6036 | 0.140 |
Why?
|
Benzazepines | 3 | 2013 | 326 | 0.140 |
Why?
|
Receptors, Opioid, mu | 1 | 2017 | 182 | 0.140 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2016 | 141 | 0.130 |
Why?
|
Benzothiazoles | 1 | 2016 | 248 | 0.130 |
Why?
|
Spinal Injuries | 1 | 1999 | 301 | 0.130 |
Why?
|
Basal Ganglia | 1 | 2018 | 546 | 0.130 |
Why?
|
Delusions | 1 | 2017 | 300 | 0.130 |
Why?
|
Models, Animal | 2 | 2021 | 2173 | 0.130 |
Why?
|
Hallucinations | 1 | 2017 | 360 | 0.130 |
Why?
|
Amines | 1 | 2016 | 276 | 0.130 |
Why?
|
Pallidotomy | 1 | 2014 | 3 | 0.130 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2014 | 48 | 0.120 |
Why?
|
Raclopride | 5 | 1999 | 97 | 0.120 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 65 | 0.120 |
Why?
|
Dizocilpine Maleate | 3 | 2009 | 176 | 0.120 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2015 | 177 | 0.120 |
Why?
|
Hormone Replacement Therapy | 1 | 2019 | 745 | 0.120 |
Why?
|
Disease Models, Animal | 7 | 2013 | 18034 | 0.110 |
Why?
|
Transglutaminases | 1 | 2014 | 194 | 0.110 |
Why?
|
Tissue Distribution | 2 | 2009 | 2327 | 0.110 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2014 | 261 | 0.110 |
Why?
|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2012 | 70 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2008 | 8949 | 0.110 |
Why?
|
Aging | 5 | 2012 | 8664 | 0.110 |
Why?
|
Serotonin 5-HT1 Receptor Antagonists | 1 | 2012 | 9 | 0.110 |
Why?
|
Prefrontal Cortex | 4 | 2000 | 2147 | 0.110 |
Why?
|
Behavior Therapy | 1 | 2018 | 865 | 0.100 |
Why?
|
Sympatholytics | 3 | 2001 | 83 | 0.100 |
Why?
|
Central Nervous System Stimulants | 3 | 2015 | 1148 | 0.100 |
Why?
|
Structure-Activity Relationship | 4 | 2012 | 3130 | 0.100 |
Why?
|
Thiophenes | 1 | 2016 | 589 | 0.100 |
Why?
|
Cocaine | 4 | 2001 | 1007 | 0.100 |
Why?
|
Hindlimb Suspension | 1 | 2012 | 83 | 0.100 |
Why?
|
Metabolome | 1 | 2018 | 895 | 0.100 |
Why?
|
Body Weight | 2 | 2021 | 4671 | 0.100 |
Why?
|
CHO Cells | 2 | 2012 | 1409 | 0.090 |
Why?
|
Substantia Nigra | 3 | 2005 | 353 | 0.090 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2016 | 1121 | 0.090 |
Why?
|
Amygdala | 1 | 1998 | 1315 | 0.090 |
Why?
|
Catalepsy | 1 | 2009 | 34 | 0.090 |
Why?
|
Cholinesterase Inhibitors | 1 | 2011 | 238 | 0.090 |
Why?
|
Cricetinae | 3 | 2012 | 2475 | 0.090 |
Why?
|
Electroconvulsive Therapy | 1 | 2015 | 477 | 0.090 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 21 | 0.090 |
Why?
|
Cricetulus | 1 | 2012 | 818 | 0.090 |
Why?
|
Alcohol Oxidoreductases | 1 | 2010 | 170 | 0.090 |
Why?
|
Exercise Therapy | 1 | 2016 | 904 | 0.090 |
Why?
|
Cholinergic Agents | 1 | 2009 | 93 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2020 | 2575 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 2031 | 0.090 |
Why?
|
Dopamine Agents | 3 | 2009 | 189 | 0.090 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 2 | 2006 | 66 | 0.080 |
Why?
|
Entorhinal Cortex | 2 | 2002 | 272 | 0.080 |
Why?
|
8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2008 | 32 | 0.080 |
Why?
|
Adult | 8 | 2021 | 214052 | 0.080 |
Why?
|
Athletic Injuries | 1 | 1999 | 1154 | 0.080 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2014 | 1157 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2007 | 2408 | 0.080 |
Why?
|
Indoles | 1 | 2016 | 1839 | 0.080 |
Why?
|
Spiperone | 4 | 1999 | 31 | 0.080 |
Why?
|
Benzamides | 5 | 2004 | 1379 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8642 | 0.080 |
Why?
|
Binding Sites | 3 | 2009 | 6111 | 0.070 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 1998 | 3617 | 0.070 |
Why?
|
Deep Brain Stimulation | 1 | 2014 | 748 | 0.070 |
Why?
|
Transcription Factors | 3 | 2014 | 12207 | 0.070 |
Why?
|
Female | 14 | 2022 | 380193 | 0.070 |
Why?
|
Drug Approval | 1 | 2012 | 742 | 0.070 |
Why?
|
Stress, Physiological | 2 | 2004 | 1403 | 0.070 |
Why?
|
Glycine | 1 | 2009 | 671 | 0.070 |
Why?
|
Cognition | 1 | 2023 | 6770 | 0.070 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2015 | 1433 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2015 | 1790 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1620 | 0.060 |
Why?
|
Random Allocation | 1 | 2009 | 2428 | 0.060 |
Why?
|
Radiosurgery | 1 | 2014 | 1329 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1584 | 0.060 |
Why?
|
Excitatory Amino Acid Agents | 1 | 2004 | 23 | 0.060 |
Why?
|
Protein Isoforms | 1 | 2009 | 1730 | 0.060 |
Why?
|
Time Factors | 7 | 2009 | 40075 | 0.060 |
Why?
|
Adoption | 1 | 2004 | 97 | 0.060 |
Why?
|
Antiparkinson Agents | 1 | 2005 | 184 | 0.060 |
Why?
|
Alkylation | 2 | 2000 | 86 | 0.060 |
Why?
|
Attention | 2 | 2012 | 2397 | 0.060 |
Why?
|
Stereoisomerism | 4 | 2008 | 624 | 0.060 |
Why?
|
Clinical Trials as Topic | 3 | 2010 | 7914 | 0.060 |
Why?
|
Morpholines | 1 | 2006 | 571 | 0.060 |
Why?
|
Mood Disorders | 1 | 2010 | 1106 | 0.060 |
Why?
|
Mice | 7 | 2012 | 81201 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2009 | 4933 | 0.060 |
Why?
|
Receptors, Serotonin, 5-HT1 | 1 | 2002 | 13 | 0.050 |
Why?
|
Homeodomain Proteins | 2 | 2009 | 2418 | 0.050 |
Why?
|
Cell Line | 3 | 2012 | 16000 | 0.050 |
Why?
|
Sympathectomy, Chemical | 1 | 2001 | 22 | 0.050 |
Why?
|
Receptor, Serotonin, 5-HT2C | 1 | 2002 | 44 | 0.050 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2002 | 170 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10388 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 21748 | 0.050 |
Why?
|
Serotonin Antagonists | 1 | 2002 | 144 | 0.050 |
Why?
|
Models, Molecular | 1 | 2012 | 5451 | 0.050 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 1107 | 0.050 |
Why?
|
Mice, Knockout | 3 | 2009 | 14561 | 0.050 |
Why?
|
Cerebellar Cortex | 1 | 2002 | 107 | 0.050 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2002 | 163 | 0.050 |
Why?
|
Infusion Pumps | 1 | 2002 | 163 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.050 |
Why?
|
Prevalence | 1 | 2018 | 15221 | 0.050 |
Why?
|
Signal Transduction | 2 | 2020 | 23404 | 0.050 |
Why?
|
Age Factors | 2 | 2009 | 18373 | 0.050 |
Why?
|
Synaptosomes | 1 | 2000 | 115 | 0.050 |
Why?
|
Methylphenidate | 2 | 2001 | 473 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2009 | 6366 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2010 | 2865 | 0.050 |
Why?
|
Functional Laterality | 1 | 2007 | 2290 | 0.050 |
Why?
|
Receptors, GABA-B | 1 | 2000 | 68 | 0.040 |
Why?
|
Amphetamine-Related Disorders | 1 | 2000 | 67 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12961 | 0.040 |
Why?
|
Symporters | 1 | 2002 | 361 | 0.040 |
Why?
|
Regression Analysis | 1 | 2009 | 6459 | 0.040 |
Why?
|
Receptors, Dopamine D5 | 1 | 1998 | 32 | 0.040 |
Why?
|
Radiopharmaceuticals | 2 | 2006 | 2645 | 0.040 |
Why?
|
Down-Regulation | 1 | 2006 | 3001 | 0.040 |
Why?
|
British Columbia | 1 | 1999 | 244 | 0.040 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 1998 | 146 | 0.040 |
Why?
|
Drug Design | 2 | 2008 | 1076 | 0.040 |
Why?
|
Memory, Short-Term | 1 | 2004 | 977 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2274 | 0.040 |
Why?
|
Receptors, GABA-A | 1 | 2002 | 627 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 2004 | 1312 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 1999 | 977 | 0.030 |
Why?
|
Deoxyglucose | 2 | 1994 | 337 | 0.030 |
Why?
|
Binge-Eating Disorder | 1 | 2017 | 137 | 0.030 |
Why?
|
GTP-Binding Proteins | 1 | 2000 | 970 | 0.030 |
Why?
|
Aminopyridines | 1 | 1999 | 542 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2003 | 1741 | 0.030 |
Why?
|
Cerebellum | 1 | 2002 | 1488 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 63107 | 0.030 |
Why?
|
Naltrexone | 1 | 2017 | 307 | 0.030 |
Why?
|
Bulimia | 1 | 2017 | 383 | 0.030 |
Why?
|
Dibenzoxazepines | 1 | 1994 | 8 | 0.030 |
Why?
|
Adolescent | 2 | 2019 | 85779 | 0.030 |
Why?
|
Biogenic Amines | 1 | 2014 | 50 | 0.030 |
Why?
|
Memory | 1 | 2004 | 2174 | 0.030 |
Why?
|
Nerve Degeneration | 1 | 1999 | 748 | 0.030 |
Why?
|
Opioid Peptides | 1 | 2014 | 42 | 0.030 |
Why?
|
Receptor, Cannabinoid, CB2 | 1 | 2014 | 49 | 0.030 |
Why?
|
Psychopathology | 1 | 2017 | 409 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9584 | 0.030 |
Why?
|
Receptor, Cannabinoid, CB1 | 1 | 2014 | 143 | 0.030 |
Why?
|
Neuroprotective Agents | 1 | 1999 | 941 | 0.030 |
Why?
|
Narcotic Antagonists | 1 | 2017 | 562 | 0.030 |
Why?
|
Frontal Lobe | 1 | 1999 | 1406 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2007 | 4245 | 0.030 |
Why?
|
Ligands | 3 | 2007 | 3282 | 0.030 |
Why?
|
Mental Disorders | 2 | 2014 | 6598 | 0.020 |
Why?
|
Glucose | 2 | 1994 | 4398 | 0.020 |
Why?
|
Risk Factors | 1 | 2018 | 72296 | 0.020 |
Why?
|
Spinal Cord Injuries | 1 | 1999 | 931 | 0.020 |
Why?
|
Neurons | 1 | 2009 | 9340 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1996 | 4320 | 0.020 |
Why?
|
Aphakia | 1 | 2009 | 24 | 0.020 |
Why?
|
Sugar Phosphates | 1 | 1989 | 43 | 0.020 |
Why?
|
Axons | 1 | 1998 | 1685 | 0.020 |
Why?
|
Inositol Phosphates | 1 | 1989 | 180 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2004 | 13035 | 0.020 |
Why?
|
Middle Aged | 2 | 2019 | 213390 | 0.020 |
Why?
|
Guanosine Triphosphate | 1 | 1989 | 321 | 0.020 |
Why?
|
History, 20th Century | 1 | 1996 | 2740 | 0.020 |
Why?
|
Esters | 1 | 2008 | 210 | 0.020 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2008 | 281 | 0.020 |
Why?
|
Fractures, Bone | 1 | 1999 | 1947 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2012 | 2029 | 0.020 |
Why?
|
Psychomotor Performance | 2 | 2005 | 1901 | 0.020 |
Why?
|
Models, Chemical | 1 | 2008 | 626 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2006 | 462 | 0.020 |
Why?
|
Restraint, Physical | 1 | 2007 | 193 | 0.020 |
Why?
|
Benserazide | 1 | 2005 | 5 | 0.020 |
Why?
|
Length of Stay | 1 | 1999 | 6311 | 0.020 |
Why?
|
Mice, Neurologic Mutants | 1 | 2005 | 126 | 0.020 |
Why?
|
Papio | 1 | 2006 | 656 | 0.020 |
Why?
|
United States | 1 | 2012 | 69872 | 0.020 |
Why?
|
Rats, Inbred SHR | 1 | 2003 | 195 | 0.010 |
Why?
|
Conditioning, Operant | 1 | 2004 | 313 | 0.010 |
Why?
|
Ataxia | 1 | 2005 | 304 | 0.010 |
Why?
|
Ketanserin | 1 | 2002 | 24 | 0.010 |
Why?
|
Affinity Labels | 1 | 2002 | 109 | 0.010 |
Why?
|
Locomotion | 1 | 2005 | 378 | 0.010 |
Why?
|
Nerve Endings | 1 | 2002 | 109 | 0.010 |
Why?
|
Azides | 1 | 2002 | 116 | 0.010 |
Why?
|
Neurotoxins | 1 | 2003 | 237 | 0.010 |
Why?
|
Culture Techniques | 1 | 2002 | 554 | 0.010 |
Why?
|
Stereotyped Behavior | 1 | 2001 | 136 | 0.010 |
Why?
|
Blindness | 1 | 2005 | 615 | 0.010 |
Why?
|
Incidence | 1 | 1999 | 20952 | 0.010 |
Why?
|
Sulfur Radioisotopes | 1 | 2000 | 116 | 0.010 |
Why?
|
Kinetics | 1 | 2008 | 6476 | 0.010 |
Why?
|
Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2000 | 87 | 0.010 |
Why?
|
Baclofen | 1 | 2000 | 129 | 0.010 |
Why?
|
Pregnancy | 3 | 2007 | 29144 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12025 | 0.010 |
Why?
|
Pyrroles | 1 | 2004 | 1146 | 0.010 |
Why?
|
Drug Interactions | 1 | 2001 | 1460 | 0.010 |
Why?
|
Calcium | 1 | 1989 | 5755 | 0.010 |
Why?
|
Pyrazines | 1 | 2001 | 1230 | 0.010 |
Why?
|
Densitometry | 1 | 1994 | 156 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 1997 | 1032 | 0.010 |
Why?
|
Models, Genetic | 1 | 2003 | 3493 | 0.010 |
Why?
|
Cell Survival | 1 | 2002 | 5882 | 0.010 |
Why?
|
Oxalic Acid | 1 | 1989 | 20 | 0.010 |
Why?
|
Vas Deferens | 1 | 1989 | 55 | 0.010 |
Why?
|
Inositol 1,4,5-Trisphosphate | 1 | 1989 | 114 | 0.010 |
Why?
|
Pyrimidines | 1 | 2001 | 2943 | 0.010 |
Why?
|
Microsomes | 1 | 1989 | 257 | 0.010 |
Why?
|
Oxalates | 1 | 1989 | 105 | 0.010 |
Why?
|
Cell Fractionation | 1 | 1989 | 252 | 0.010 |
Why?
|
Cell Membrane | 1 | 1999 | 3749 | 0.010 |
Why?
|
Intracellular Membranes | 1 | 1989 | 391 | 0.010 |
Why?
|
Thalamus | 1 | 1994 | 1023 | 0.000 |
Why?
|
Genetic Variation | 1 | 2003 | 6542 | 0.000 |
Why?
|
Cell Membrane Permeability | 1 | 1989 | 590 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 2005 | 21833 | 0.000 |
Why?
|
Aged | 1 | 1999 | 163288 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2002 | 19233 | 0.000 |
Why?
|
Muscle, Smooth | 1 | 1989 | 934 | 0.000 |
Why?
|
Biological Transport | 1 | 1989 | 2120 | 0.000 |
Why?
|
Endoplasmic Reticulum | 1 | 1989 | 1146 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 1999 | 35425 | 0.000 |
Why?
|